期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到91篇文章
< 1 2 … 5 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Cardiovascular outcomes of sodium-glucose co-transporter-2 inhibitors in heart failure and coexisting chronic obstructive pulmonary disease:A meta-analysis 认领 引用
1
作者 Zaraq Ahmad Khan Rohab Sohail +10 位作者 Ridda Khattak Vyom Patel Marcos Alberto Jr Prakhar Anand Andrei Feldiorean Mark Georgy Lindsey Marie Valdiviez David Poldneff Zoraiz Khan Ibraheem Murtaza Shawn Curry 《World Journal of Cardiology》 2026年第6期106-114,共9页
BACKGROUND Sodium-glucose co-transporter-2 inhibitors(SGLT-2Is),originally developed as anti-hyperglycemic medications,have emerged as cornerstone therapies for heart failure(HF)due to their cardioprotective effects.W... BACKGROUND Sodium-glucose co-transporter-2 inhibitors(SGLT-2Is),originally developed as anti-hyperglycemic medications,have emerged as cornerstone therapies for heart failure(HF)due to their cardioprotective effects.While their mortality benefits in HF are established,their role in patients with both HF and chronic obstructive pulmonary disease(COPD)remains unclear.AIM To evaluate the effects of SGLT-2Is in patients with HF with coexisting COPD,focusing on hospitalization,cardiovascular(CV)mortality,and drug-related complications.METHODS A systematic search of PubMed and Cochrane Library databases was conducted through February 17,2025,for randomized controlled trials assessing the safety and efficacy of SGLT-2I in HF patients with coexistent COPD.Outcomes analyzed included composite first hospitalization for HF(HHF),CV death,all-cause mortality,and time-to-first HHF.Safety endpoints included drug discontinuation,serious adverse events(AE),volume depletion,major hypoglycemia,and renal AE,reported as relative risk(RR)with 95%confidence intervals.RESULTS Four trials(n=3224)met inclusion criteria.Of these,1727 patients(53.6%)received SGLT-2Is,while 46.4%received placebo.Compared with placebo,SGLT-2I significantly reduced the risk of composite HHF+CV death(RR=0.80,95%CI:0.70-0.91,P=0.0006,I2=0%),HHF(RR=0.77,95%CI:0.67-0.88,P<0.0001,I2=0%),and time-to-first HHF(RR=0.75,95%CI:0.57-0.99,P=0.04,I2=47%).No significant differences were observed for CV death(RR=1.01,P=0.88)or all-cause mortality(RR=0.94,P=0.46).SGLT-2I did not increase risk of drug discontinuation,serious AE,renal AE,volume depletion,nor hypoglycemia.CONCLUSION In patients with HF and COPD,SGLT-2Is significantly reduce HF hospitalizations but do not lower all-cause mortality or CV mortality.Importantly,these drugs are well tolerated without excess AE,supporting their role as a safe therapeutic option in this population. 展开更多
关键词 Chronic obstructive pulmonary disease Heart failure Sodium-glucose co-transporter-2 inhibitors Sodium-glucose co-transporter-2 Cardioprotective Dapagliflozin Empagliflozin
暂未订购 下载PDF
Investigation of interaction between sodium-glucose cotransporter 2 inhibitors and FOLFOX with colorectal cancer and type 2 diabetes 认领 引用
2
作者 Bin Liu Ning Su +2 位作者 Qing-Shi Lin Yan-Qin Huang Shao-Feng Chen 《World Journal of Gastrointestinal Oncology》 SCIE 2026年第6期257-266,共10页
BACKGROUND For stage III colorectal cancer(CRC)patients with type 2 diabetes mellitus(T2DM),the standard mFOLFOX6 adjuvant chemotherapy is often challenged by disease recurrence and chemotherapy-induced toxicities.Sod... BACKGROUND For stage III colorectal cancer(CRC)patients with type 2 diabetes mellitus(T2DM),the standard mFOLFOX6 adjuvant chemotherapy is often challenged by disease recurrence and chemotherapy-induced toxicities.Sodium-glucose cotransporter 2(SGLT2)inhibitors,beyond glycemic control,exhibit potential antitumor properties in preclinical studies,yet robust clinical evidence for their combination with FOLFOX is scarce.We hypothesized that adding the SGLT2 inhibitor dapagliflozin to mFOLFOX6 would improve glycemic control,enhance oncological outcomes,and not significantly increase chemotherapy-related toxicities in this comorbid patient population.AIM To investigate the efficacy and safety of dapagliflozin combined with mFOLFOX6 in stage III CRC patients with T2DM.METHODS This single-center,randomized controlled trial at a tertiary hospital enrolled 160 patients with stage III CRC and T2DM post-R0 resection.They were assigned to receive either dapagliflozin plus mFOLFOX6(experimental group)or mFOLFOX6 with standard non-SGLT2 inhibitors glucose management(control group)for 12 cycles.Key outcomes included 3-year disease-free survival(DFS),tumor markers(carcinoembryonic antigen,carbohydrate antigen 19-9),glycemic control(glycated hemoglobin,fasting blood glucose),and adverse events.Data were analyzed using t-tests,χ2 tests,and Kaplan-Meier with log-rank test.RESULTS The experimental group(n=80)showed superior glycemic control(post-treatment glycated hemoglobin:6.79%±0.79%vs 7.75%±0.59%,P<0.001)and greater reductions in tumor markers(post-treatment carcinoembryonic antigen:3.59±1.24 ng/mL vs 4.52±1.15 ng/mL,P<0.001)compared to the control group(n=80).The 3-year DFS was significantly higher(43.75%vs 22.5%,P=0.004),with a prolonged median DFS(31.6 months vs 19.0 months,P<0.001).The incidence of grade≥3 chemotherapy-related adverse events was not significantly different between groups(56.25%vs 47.5%,P=0.268).Specific SGLT2 inhibitor-associated events(e.g.,acute kidney injury,diabetic ketoacidosis)occurred but were manageable.CONCLUSION Adding dapagliflozin to mFOLFOX6 improves glycemic control,tumor marker response,and survival in stage III CRC patients with T2DM,without significantly increasing chemotherapy-specific toxicities. 展开更多
关键词 Sodium-glucose cotransporter 2 inhibitors Colorectal cancer mFOLFOX6 Type 2 diabetes mellitus Survival rate Dapagliflozin
暂未订购 下载PDF
Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes fasting during Ramadan:A meta-analysis 认领 引用
3
作者 Abul Bashar Mohammad Kamrul-Hasan Shehla Shaikh +4 位作者 Hamid Ashraf Mohammad Shafi Kuchay Lakshmi Nagendra Deep Dutta Joseph M Pappachan 《World Journal of Diabetes》 SCIE 2026年第2期228-242,共15页
BACKGROUND Sodium-glucose cotransporter-2 inhibitors(SGLT2i)are widely used in managing type 2 diabetes(T2D).A significant number of these patients choose to observe religious fasting during Ramadan.Although existing ... BACKGROUND Sodium-glucose cotransporter-2 inhibitors(SGLT2i)are widely used in managing type 2 diabetes(T2D).A significant number of these patients choose to observe religious fasting during Ramadan.Although existing guidelines recommend caution when administering SGLT2i during Ramadan due to potential adverse effects,there is limited data on their use in this patient population.AIM To assess the safety and effectiveness of SGLT2i in patients with T2D who fast during Ramadan.METHODS Relevant studies involving adults with T2D who received an SGLT2i in the intervention arm and other glucoselowering drugs in the control arm were systematically searched through electronic databases.The primary outcome was the occurrence of adverse events in the two groups;additional outcomes included changes in glycemic and anthropometric parameters during the peri-Ramadan period.RevMan Web was used to conduct meta-analysis using random-effects models.Outcomes were presented as mean differences(MDs)or risk ratios(RRs)with 95%CI.RESULTS Twelve studies involving 3625 subjects were included.The risks of postural dizziness(RR=6.39,95%CI:1.58-25.80,P=0.009,I2=44%),hypotension/postural hypotension(RR=4.43,95%CI:1.35-14.55,P=0.01,I2=31%),and sodium loss(MD=-1.00 mmol/L,95%CI:-1.34 to-0.67,P<0.00001,I2=0%)were higher in the SGLT2i group compared to the non-SGLT2i group.The SGLT-2i group achieved larger reductions in systolic(MD=-2.41 mmHg,95%CI:-4.52 to-0.30,P=0.02,I2=46%)and diastolic blood pressure(MD=-1.71 mmHg,95%CI:-2.70 to-0.72,P=0.0007,I2=20%),and experienced a lower risk of symptomatic hypoglycemia(RR=0.53,95%CI:0.29-0.97,P=0.04,I2=69%).The two groups exhibited comparable changes in glycated hemoglobin,body weight,and renal function.The risks of other specific adverse events,including dehydration,dizziness,volume depletion,symptomatic hyperglycemia,severe hypoglycemia,and genitourinary infections,were identical in the two groups.CONCLUSION SGLT2i may be generally safe and effectively manage T2D during Ramadan;however,the results are less robust and should be interpreted with caution.Large multicenter randomized trials are necessary to confirm their safety,especially for at-risk groups,and to improve clinical decision-making. 展开更多
关键词 Type 2 diabetes Sodium-glucose cotransporter-2 inhibitors Ramadan Religious fasting Safety Meta-analysis
暂未订购 下载PDF
Letter to the Editor:Ca2+/calmodulin-dependent protein kinase Ⅱ in heart failure and the role of sodium-glucose-cotransporter 2 inhibitors 认领 引用
4
作者 Yi-Fei Zhang Wu-Xiao Yang Xue-Wen Li 《World Journal of Cardiology》 2026年第4期119-125,共7页
We read with great interest the meta-analysis by Parsi et al showing the strong therapeutic effects of sodium-glucose cotransporter-2 inhibitors(SGLT2i)in heart failure.Because the expression of sodium-glucose cotrans... We read with great interest the meta-analysis by Parsi et al showing the strong therapeutic effects of sodium-glucose cotransporter-2 inhibitors(SGLT2i)in heart failure.Because the expression of sodium-glucose cotransporter-2 in cardiomyocytes is minimal,the exact pathways for their direct cardioprotective actions are not fully defined.In this correspondence,we summarize emerging evidence and advance an integrated view that places Ca2+/calmodulin-dependent protein kinase Ⅱ(CaMKⅡ)as a central molecular target.CaMKⅡ is a key factor in heart failure progression.By phosphorylating a host of key substrates such as ryanodine receptor 2,L-type calcium channels and voltage-gated sodium channel voltage-gated sodium channel type Ⅴ 1.5,it facilitates ionic imbalance,predisposition to arrhythmia,and structural remodeling.We highlight the way SGLT2i may exercise their benefits through coordinated suppression of CaMKⅡ activity via enhanced ionic homeostasis,decreased oxidative injury and suppressed inflammatory signaling.This mechanistic framework offers a unified explanation for the reported clinical and experimental improvements associated with SGLT2i,such as improved electrical stability,improved systolic and diastolic function,and reduction of pathological cardiac remodeling. 展开更多
关键词 Sodium-glucose cotransporter 2 inhibitor Heart failure Ca2+/calmodulindependent protein kinaseⅡ Oxidative stress Calcium homeostasis
暂未订购 下载PDF
Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and β-cell function in type 2 diabetes: A meta-analysis 认领 引用 被引量：1
5
作者 Shang-Yu Chai Ru-Ya Zhang +3 位作者 Zhi-Yuan Ning Yi-Man Zheng Rajpathak Swapnil Li-Nong Ji 《World Journal of Diabetes》 SCIE 2025年第7期354-369,共16页
BACKGROUND Sodium-glucose cotransporter 2(SGLT2)inhibitors are widely used for the tr-eatment of type 2 diabetes(T2D).AIM To evaluate the influence of SGLT2 inhibitors on homeostasis model assessment of insulin resist... BACKGROUND Sodium-glucose cotransporter 2(SGLT2)inhibitors are widely used for the tr-eatment of type 2 diabetes(T2D).AIM To evaluate the influence of SGLT2 inhibitors on homeostasis model assessment of insulin resistance(HOMA-IR)andβ-cell function(HOMA-β)in patients with T2D in a meta-analysis.METHODS Randomized controlled trials(RCTs)comparing SGLT2 inhibitors to placebo in T2D patients,with a minimum treatment duration of 12 weeks,were searched using the PubMed,EMBASE,and Cochrane Library databases.Risk of bias was assessed using the Cochrane Risk of Bias Tool,and the certainty of evidence was evaluated using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)system.Changes in HOMA-IR and HOMA-βwere the outcomes analyzed.Meta-analyses were performed using a random-effects model by incorporating the potential influences of heterogeneity.RESULTS Of 1388 articles identified,24 RCTs met the inclusion criteria.23 of the included studies were double-blind RCTs with low risk of bias.Pooled results including 2272 patients showed that SGLT2 inhibitors significantly reduced HOMA-IR compared to placebo[mean difference(MD)=-0.81,95%confidence interval(CI):-1.11 to-0.52,P0.05).CONCLUSION SGLT2 inhibitors are associated with improvements in insulin resistance andβ-cell function in patients with T2D,although the certainty of evidence is moderate due to heterogeneity. 展开更多
关键词 β-cell function Homeostasis model assessment Insulin resistance Meta-analysis Sodium-glucose co-transporter 2 inhibitors
暂未订购 下载PDF
Shedding light on the effects of sodium-glucose cotransporter 2 inhibitors in the early stages of heart failure 认领 引用
6
作者 Luigi Falco Emilio Di Lorenzo Daniele Masarone 《World Journal of Cardiology》 2025年第3期96-100,共5页
Heart failure(HF),which falls outside of the historical macrovascular or microvascular categorizations of diabetes complications,has been overlooked for long time in diabetic patients,despite its increasing prevalence... Heart failure(HF),which falls outside of the historical macrovascular or microvascular categorizations of diabetes complications,has been overlooked for long time in diabetic patients,despite its increasing prevalence and mortality.As originally stated in the Framingham studies,diabetes is associated with an increased risk of HF.Subsequent studies not only corroborated these findings but also identified HF as the most frequent first onset of cardiovascular involvement.The paramount role of proper management of common modifiable risk factors such as hypertension,obesity,dyslipidemia and smoking,became rapidly clear.Conversely,the impact of intensive glycemic control was more contentious.A large meta-analysis of randomized controlled trials reported a lack of effect of strict glycemic control as compared to standard care on HF-related outcomes.The considerable heterogeneity of the effect estimate and the higher risk conferred by thiazolidinediones suggested that mechanism of action of antidiabetic drugs played a key role.Furthermore,the safety concerns of pioglitazone led Food and Drug Administration to release a guidance for drug manufacturers stating that cardiovascular risk should be comprehensively evaluated during drug development.Surprisingly,in just a few years,large cardiovascular outcome trials established the beneficial cardiovascular effects of sodium-glucose cotransporter 2 inhibitors.These effects were consistent regardless diabetes and ejection fraction.Therefore,scientific community started to question the glucose-lowering and diuretic properties of sodium-glucose cotransporter 2 inhibitors as the unique mechanisms for improved outcomes.A plenty of preclinical and clinical studies identified several mechanisms besides glucose-lowering effects.However,these mechanistic studies focused on animal models and patients with established HF.If the same mechanisms account for beneficial effects in patients at risk for or with pre-HF is unknown.Grubić Rotkvićet al published an interesting work adding data in early stages HF. 展开更多
关键词 Heart failure Sodium-glucose cotransporter 2 Sodium-glucose cotransporter 2 inhibitors Diabetes complications Glycemic control
暂未订购 下载PDF
Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection 认领 引用
7
作者 Yoo-Ri Chung Chungwoon Kim +1 位作者 Eunzee Lee Kihwang Lee 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2025年第7期1326-1332,共7页
AIM:To investigate the effects of dipeptidyl peptidase-4 inhibitors(DPP4i)and sodium-glucose cotransporter-2 inhibitors(SGLT2i)on diabetic macular edema(DME)and the need for intravitreal injections(IVT)in patients wit... AIM:To investigate the effects of dipeptidyl peptidase-4 inhibitors(DPP4i)and sodium-glucose cotransporter-2 inhibitors(SGLT2i)on diabetic macular edema(DME)and the need for intravitreal injections(IVT)in patients with type 2 diabetes.METHODS:Data were retrospectively collected from the medical records of patients with diabetic retinopathy(DR)taking either DPP4i or SGLT2i as secondary oral hypoglycemic agents in addition to metformin between January 2019 and July 2022.We compared the prevalence of DME and the need for IVT among patients treated with DPP4i or SGLT2i.Propensity score matching was performed using the following variables:age,duration of diabetes,blood glucose control(HbA1c)level,and severity of DR.RESULTS:A total of 268 patients with DR were included in this study.More DPP4i users needed IVT than SGLT2i users(35.3%vs 18.0%,P=0.011),while the prevalence of DME was not different.The use of SGLT2i was associated with a lower need for IVT than DPP4i[odds ratio(OR)0.404,95%confidence interval(CI)0.198-0.823],and similar trends were observed after propensity score matching(OR 0.419,95%CI 0.181-0.970).However,this tendency was not significant in multiple logistic regressions.For DME,the use of DPP4i was not a significant risk factor compared to SGLT2i.CONCLUSION:The use of SGLT2i may be associated with a lower need for IVT for overall DR complications,while other factors may contribute to this effect.The effect of SGLT2i on the prevention of DME is not evident. 展开更多
关键词 diabetic macular edema diabetic retinopathy dipeptidyl peptidase-4 inhibitor intravitreal injection sodium-glucose cotransporter-2 inhibitor
暂未订购 下载PDF
Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagonlike peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort 认领 引用
8
作者 Di-Fei Lu Rui Zheng +1 位作者 Ang Li Jun-Qing Zhang 《World Journal of Diabetes》 SCIE 2025年第2期123-132,共10页
BACKGROUND With accumulating evidence showing a benefit in the renal and cardiovascular systems,diabetes guidelines recommend that patients with diabetes and chronic kidney disease(CKD)be treated with sodium-glucose c... BACKGROUND With accumulating evidence showing a benefit in the renal and cardiovascular systems,diabetes guidelines recommend that patients with diabetes and chronic kidney disease(CKD)be treated with sodium-glucose cotransporter-2 inhibitor(SGLT2i)and/or glucagon like peptide-1 receptor agonists(GLP-1RAs)for renal protection.The real-world efficacy of the two medications on the urinary albumin-creatinine ratio(UACR)and estimated glomerular filtration rate(eGFR)remains to be explored.AIM To evaluate the SGLT2i and GLP-1RA application rates and UACR alterations after intervention in a real-world cohort of patients with diabetes.METHODS A cohort of 5482 patients with type 2 diabetes were enrolled and followed up at the Integrated Care Clinic for Diabetes of Peking University First Hospital for at least 6 months.Propensity score matching was performed,and patients who were not recommended for GLP-1RA or SGLT2i with comparable sex categories and ages were assigned to the control group at a 1:2 ratio.Blood glucose,body weight,UACR and eGFR were evaluated after 6 months of treatment in real-world clinical practice.RESULTS A total of 139(2.54%)patients started GLP-1RA,and 387(7.06%)received SGLT2i.After 6 months,the variations in fasting blood glucose,prandial blood glucose,and glycosylated hemoglobin between the GLP-1RA group and the SGLT2i and control groups were not significantly different.UACR showed a tendency toward a greater reduction compared with the control group,although this difference was not statistically significant(GLP-1RA vs control,-2.20 vs 30.16 mg/g,P=0.812;SGLT2i vs control,-20.61 vs 12.01 mg/g,P=0.327);eGFR alteration also showed no significant differences.Significant weight loss was observed in the GLP-1RA group compared with the control group(GLP-1RA vs control,-0.90 vs 0.27 kg,P<0.001),as well as in the SGLT2i group(SGLT2i vs control,-0.59 vs-0.03 kg,P=0.010).CONCLUSION Compared with patients who received other glucose-lowering drugs,patients receiving SGLT2i or GLP-1RAs presented significant weight loss,a decreasing trend in UACR and comparable glucose-lowering effects in realworld settings. 展开更多
关键词 Type 2 diabetes Chronic kidney disease Body weight Sodium-glucose cotransporter-2 inhibitors Glucagon-like peptide-1 receptor agonists
暂未订购 下载PDF
Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage 认领 引用
9
作者 María M Adeva-Andany 《World Journal of Nephrology》 2025年第4期147-158,共12页
Sodium-glucose cotransporter-2(SGLT2)inhibitors suppress glucose reabsorption in the kidney proximal tubule through the SGLT2 protein,leading to glucosuria and osmotic diuresis.Randomized placebo-controlled clinical t... Sodium-glucose cotransporter-2(SGLT2)inhibitors suppress glucose reabsorption in the kidney proximal tubule through the SGLT2 protein,leading to glucosuria and osmotic diuresis.Randomized placebo-controlled clinical trials show that SGLT2 inhibitors increase long-term estimated glomerular filtration rate(GFR),calculated with serum creatinine-based equations.However,this effect of SGLT2 inhibitors may not reflect an improvement of kidney function.Investigations conducted in healthy volunteers and patients with chronic kidney disease and population-based studies reveal a positive association between urinary osmolality and GFR,either measured or estimated,indicating that glucosuria and osmotic diuresis are associated with glomerular hyperfiltration.Further,glomerular hyperfiltration is magnified by animal meat consumption.Therefore,the elevation of estimated GFR observed in patients receiving SGLT2 inhibitors may represent an adaptive response to glucosuria and osmotic diuresis driven by these drugs rather than an improvement of kidney function.Additionally,SGLT2 inhibitors have been consistently associated with loss of skeletal muscle mass.Reduction of muscle mass lowers serum creatinine.Serum creatinine-based equations to evaluate GFR overestimate kidney function in patients with reduced muscle mass.In patients receiving SGLT2 inhibitors,estimation of GFR using serum creatinine formulas may yield misleading high values of GFR that do not reflect a beneficial effect on kidney function. 展开更多
关键词 Sodium-glucose cotransporter-2 inhibitors Estimated glomerular filtration rate Glomerular hyperfiltration osmotic diuresis Glucosuria Skeletal muscle mass Serum creatinine-based estimation of glomerular filtration rate Kidney function overestimation
暂未订购 下载PDF
Sodium-glucose cotransporter 2 inhibitor in heart failure patients and their outcomes: A meta-analysis of randomized controlled trials 认领 引用 被引量：1
10
作者 Saketh Parsi Pallavi D Shirsat +2 位作者 Lakshmi P Mahali Salim Surani Rahul Kashyap 《World Journal of Cardiology》 2025年第10期120-129,共10页
BACKGROUND The use of sodium-glucose cotransporter 2(SGLT2)inhibitor in heart failure(HF)patients is increasing significantly,regardless of whether they have a history of diabetes.The effects of SGLT2 inhibitor on HF ... BACKGROUND The use of sodium-glucose cotransporter 2(SGLT2)inhibitor in heart failure(HF)patients is increasing significantly,regardless of whether they have a history of diabetes.The effects of SGLT2 inhibitor on HF are likely mediated through multiple mechanisms,including suppression of the renin-angiotensin-aldosterone system(RAAS),reduction in oxidative stress leading to enhanced myocardial efficiency,and attenuation of adverse cardiac remodeling by preventing fibrosis.These pathways are fundamental to reducing mortality,improving patients'quality of life,and alleviating the burden on the United States healthcare system by decreasing HF-related hospitalizations.AIM To evaluate SGLT2 inhibitor effects on HF,focusing on hospitalization for HF(HHF),cardiovascular(CV)deaths,and all-cause mortality.METHODS A comprehensive search was conducted in PubMed for randomized controlled trials(RCTs)evaluating the effects of SGLT2 inhibitor in HF patients compared to placebo,covering the period from January 1,2014,to January 1,2025.The primary outcomes assessed were HHF,CV deaths,and all-cause mortality.RevMan Web 5.4.1 was used to assess the risk of bias heterogeneity and to perform the statistical analyses.A random-effects model was employed for all statistical evaluations.RESULTS A total of nine RCTs were included in this analysis:DELIVER,DECLARE-TIMI 58,DAPA-HF,EMPA-REG OUTCOME,EMPEROR-Reduced,EMPEROR-Preserved,SOLOIST-WHF,EMPULSE,and VERTIS-CV.For HHF,eight trials(excluding the SOLOIST-WHF;n=25906)were pooled,while CV deaths were assessed using data from eight trials(excluding the EMPULSE;n=26598).Compared to placebo,SGLT2 inhibitor significantly reduced the risk of HHF(relative risk:0.74;95%CI:0.71-0.77;P<0.00001)and CV death(odds ratio:0.88;95%CI:0.83-0.92;P=0.0006).All nine trials(n=27128)were included in the analysis of all-cause mortality.SGLT2 inhibitor were associated with a statistically significant reduction in all-cause mortality compared to placebo(OR:0.91;95%CI:0.84-0.98;P=0.02).CONCLUSION These results suggest that SGLT2 inhibitor significantly reduce the risk of hospitalization for HF,CV deaths,and all-cause mortality. 展开更多
关键词 Sodium-glucose cotransporter 2 inhibitor Heart failure Hospitalizations for heart failure Cardiovascular deaths All-cause mortality
暂未订购 下载PDF
Beyond glycemic control:Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease 认领 引用 被引量：1
11
作者 Gabriel LC Santos Clara FSM dos Santos +7 位作者 Gabriel R Rocha Mariana S Calmon Fabian FB Lemos Luis GO Silva Marcel S Luz Samuel LR Pinheiro Anelise CS Botelho Fabrício F de Melo 《World Journal of Diabetes》 SCIE 2025年第6期35-57,共23页
The global prevalence of diabetes has surged in recent years,with diabetic kidney disease(DKD)emerging as a major complication.Traditional therapies have had limited success in slowing progression to end-stage kidney ... The global prevalence of diabetes has surged in recent years,with diabetic kidney disease(DKD)emerging as a major complication.Traditional therapies have had limited success in slowing progression to end-stage kidney disease.However,novel therapies,particularly sodium-glucose cotransporter 2(SGLT2)inhibitors and glucagon-like peptide-1(GLP-1)receptor agonists,which were initially developed for hyperglycemia management,have transformed the treatment of obesity,heart failure,cardiovascular disease,and more recently,DKD.SGLT2 inhibitors have consistently and significantly reduced cardiovascular events,albuminuria,and glomerular filtration rate,highlighting their efficacy across diverse clinical presentations for patients with kidney impairment.Although fewer studies have specifically investigated GLP-1 receptor agonists in patients with kidney disease,existing evidence underscores their potential to slow renal disease progression,reduce albuminuria,and improve clinically relevant outcomes.However,further research is needed to better identify patients most likely to benefit from treatment.Together,these therapies represent valuable advancements for DKD,offering significant reductions in morbidity and mortality and shifting the management of the disease by becoming essential pillars for the treatment of these patients. 展开更多
关键词 Sodium-glucose cotransporter 2 inhibitors Glucagon-like peptide-1 receptor agonists Chronic kidney disease Diabetic kidney disease Type 2 diabetes Diabetes mellitus
暂未订购 下载PDF
Impact of sodium-glucose cotransporter-2 inhibitors on pulmonary vascular cell function and arterial remodeling 认领 引用
12
作者 Jing-Jing Zhang Xue-Rui Ye +2 位作者 Xue-Song Liu Hao-Ling Zhang Qian Qiao 《World Journal of Cardiology》 2025年第1期28-46,共19页
Sodium-glucose cotransporter-2(SGLT-2)inhibitors represent a cutting-edge class of oral antidiabetic therapeutics that operate through selective inhibition of glucose reabsorption in proximal renal tubules,consequentl... Sodium-glucose cotransporter-2(SGLT-2)inhibitors represent a cutting-edge class of oral antidiabetic therapeutics that operate through selective inhibition of glucose reabsorption in proximal renal tubules,consequently augmenting urinary glucose excretion and attenuating blood glucose levels.Extensive clinical investigations have demonstrated their profound cardiovascular efficacy.Parallel basic science research has elucidated the mechanistic pathways through which diverse SGLT-2 inhibitors beneficially modulate pulmonary vascular cells and arterial remodeling.Specifically,these inhibitors exhibit promising potential in enhancing pulmonary vascular endothelial cell function,suppressing pulmonary smooth muscle cell proliferation and migration,reversing pulmonary arterial remodeling,and maintaining hemodynamic equilibrium.This comprehensive review synthesizes current literature to delineate the mechanisms by which SGLT-2 inhibitors enhance pulmonary vascular cell function and reverse pulmonary remodeling,thereby offering novel therapeutic perspectives for pulmonary vascular diseases. 展开更多
关键词 Sodium-glucose cotransporter-2 inhibitors Pulmonary vascular endothelial cells Pulmonary vascular smooth muscle cells Pulmonary artery remodeling Right heart dysfunction Cardiovascular disease
暂未订购 下载PDF
Sodium-glucose cotransporter-2 inhibitors beyond glycemic control:Their role in acute kidney injury recovery 认领 引用
13
作者 Muhammad Umar Ahsan Sana Iftikhar +4 位作者 Umme E Ambreen Fahad Nazir Matia Fawad Khadija Nasir Ume Roman Leghari 《World Journal of Nephrology》 2025年第4期165-170,共6页
With notable Reno protective advantages beyond glycemic management,sodiumglucose cotransporter-2(SGLT2)inhibitors have become a mainstay treatment for type 2 diabetes mellitus and chronic kidney disease(CKD).Although ... With notable Reno protective advantages beyond glycemic management,sodiumglucose cotransporter-2(SGLT2)inhibitors have become a mainstay treatment for type 2 diabetes mellitus and chronic kidney disease(CKD).Although SGLT2 inhibitors'involvement in the course of CKD has been well investigated,new research indicates that they may also have protective benefits in acute kidney injury(AKI),a condition for which there are few pharmacological treatments.The possible ways that SGLT2 inhibitors aid in AKI recovery are examined in this mini-review.These include mitochondrial protection,oxidative stress attenuation,anti-inflammatory effects,intraglomerular pressure decrease,and modulation of tubuloglomerular feedback.Although there is a lack of solid clinical trial data,preclinical models and observational studies suggest that SGLT2 inhibitors may lessen ischemia-reperfusion injury and contrast-induced nephropathy.This review addresses the possibility of incorporating SGLT2 inhibitors into AKI care regimens,critically evaluates the available data,and highlights important research gaps.Robust clinical trials are required to determine the safety,effectiveness,and ideal treatment window of SGLT2 inhibitors in this context,given the burden of AKI-related morbidity and mortality. 展开更多
关键词 Sodium-glucose cotransporter-2 inhibitors Acute kidney injury Renal protection Ischemia-reperfusion Oxidative stress Tubuloglomerular feedback
暂未订购 下载PDF
Role of sodium-glucose cotransporter 2 inhibitors in liver diseases 认领 引用
14
作者 Prajna Anirvan Suprabhat Giri +1 位作者 Sayan Malakar Dibya Lochan Praharaj 《World Journal of Experimental Medicine》 2025年第4期69-83,共15页
Sodium-glucose cotransporter 2(SGLT2)inhibitors compete with the SGLT2 protein for glucose binding in the renal tubules,reducing glucose reabsorption in the kidneys.This in turn leads to increased excretion of glucose... Sodium-glucose cotransporter 2(SGLT2)inhibitors compete with the SGLT2 protein for glucose binding in the renal tubules,reducing glucose reabsorption in the kidneys.This in turn leads to increased excretion of glucose,sodium,and water into the urine.These inhibitors,initially developed for diabetes management,have shown potential benefits beyond glycemic control,impacting liver health through various mechanisms.They have emerged as promising agents in managing liver conditions,including fatty liver disease,cirrhosis,and the prevention of hepatocellular carcinoma(HCC).They modulate processes like oxidative stress,inflammation,and autophagy,which are implicated in metabolic dysfunction-associated steatotic liver disease pathogenesis,potentially reducing steatosis and inflammation and preventing progression to more severe liver conditions.In patients with liver cirrhosis,SGLT2 inhibitors have been associated with a reduced need for large-volume paracentesis and lower mortality rates,indicating their potential in managing diuretic-resistant ascites.SGLT2 inhibitors have shown potential in modulating molecular pathways involved in HCC,such as inflammatory responses and oxidative stress,that could justify their use in the prevention of HCC and improving survival in patients with HCC.The present review synthesized findings from multiple studies to elucidate the role of SGLT2 inhibitors in these liver conditions. 展开更多
关键词 Sodium-glucose cotransporter 2 inhibitors Dapagliflozin Empaglifozin Metabolic dysfunction-associated steatotic liver disease Cirrhosis
暂未订购 下载PDF
Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management 认领 引用
15
作者 Xiao-Peng Fu 《World Journal of Clinical Cases》 2025年第14期61-64,共4页
The study by Lin et al delves into the clinical impact of dapagliflozin,a repre-sentative sodium-glucose cotransporter 2(SGLT2)inhibitor,on chronic heart failure complicated by hyperuricemia.This investigation highlig... The study by Lin et al delves into the clinical impact of dapagliflozin,a repre-sentative sodium-glucose cotransporter 2(SGLT2)inhibitor,on chronic heart failure complicated by hyperuricemia.This investigation highlights dapagliflo-zin’s efficacy in lowering serum uric acid levels,enhancing cardiac function,and reducing cardiovascular events.This work not only provides a comprehensive analysis of dapagliflozin’s sustained benefits in these patients but also introduces novel insights for managing chronic heart failure exacerbated by elevated uric acid.Furthermore,this review examines the potential role of SGLT2 inhibitor in the context of gout,evaluating its mechanisms and clinical application prospects in the management of hyperuricemia,thereby further enriching the medical community’s understanding of SGLT2 inhibitor. 展开更多
关键词 Sodium-glucose cotransporter 2 inhibitors Hyperuricemia Gout Uric acid reduction Chronic heart failure
暂未订购 下载PDF
Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis:A meta summary of case reports 认领 引用 被引量：5
16
作者 Deven Juneja Prashant Nasa +1 位作者 Ravi Jain Omender Singh 《World Journal of Diabetes》 SCIE 2023年第8期1314-1322,共9页
BACKGROUND Sodium-glucose cotransporter-2 inhibitors(SGLT2i)are commonly prescribed to manage patients with diabetes mellitus.These agents may rarely lead to the development of euglycemic diabetic ketoacidosis(EDKA),w... BACKGROUND Sodium-glucose cotransporter-2 inhibitors(SGLT2i)are commonly prescribed to manage patients with diabetes mellitus.These agents may rarely lead to the development of euglycemic diabetic ketoacidosis(EDKA),which may complicate the disease course of these patients.AIM To analyze the demographic profile,predisposing factors,symptomology,clinical interventions and outcomes of patients presenting with EDKA secondary to SGLT2i use by reviewing the published case reports and series.METHODS We performed a systematic search of PubMed,Science Direct,Google Scholar and Reference Citation Analysis databases using the terms“canagliflozin”OR“empagliflozin”OR“dapagliflozin”OR“SGLT2 inhibitors”OR“Sodium-glucose cotransporter-2”AND“euglycemia”OR“euglycemic diabetic ketoacidosis”OR“metabolic acidosis”.The inclusion criteria were:(1)Case reports or case series with individual patient details;and(2)Reported EDKA secondary to SGLT2i.Furthermore,the data were filtered from the literature published in the English language and on adults(>18 years).We excluded:(1)Conference abstracts;and(2)Case reports or series which did not have individual biochemical data.All the case reports and case series were evaluated.The data extracted included patient demographics,clinical symptomatology,clinical interventions,intensive care unit course,need for organ support and outcomes.RESULTS Overall,108 case reports and 17 cases series with 169 unique patients that met all the inclusion criteria were included.The majority of patients were females(54.4%,n=92),and the commonly reported symptoms were gastrointestinal(nausea/vomiting 65.1%,abdominal pain 37.3%)and respiratory(breathlessness 30.8%).One hundred and forty-nine(88.2%)patients had underlying type II diabetes,and the most commonly involved SGLT-2 inhibitor reported was empagliflozin(46.8%).A triggering factor was reported in most patients(78.7%),the commonest being acute severe infection(37.9%),which included patients with sepsis,coronavirus disease 2019,other viral illnesses,and acute pancreatitis.61.5%were reported to require intensive unit care,but only a minority of patients required organ support in the form of invasive mechanical ventilation(13%),vasopressors(6.5%)or renal replacement therapy(5.9%).The overall mortality rate was only 2.4%.CONCLUSION Patients on SGLT2i may rarely develop EDKA,especially in the presence of certain predisposing factors,including severe acute infections and following major surgery.The signs and symptoms of EDKA may be similar to that of DKA but with normal blood sugar levels,which may make the diagnosis challenging.Outcomes of EDKA are good if recognized early and corrective actions are taken.Hence,physicians managing such patients must be aware of this potential complication and must educate their patients accordingly to ensure early diagnosis and management. 展开更多
关键词 Canagliflozin Empagliflozin Euglycemia Diabetes mellitus Diabetic ketoacidosis Sodium-glucose cotransporter-2 inhibitors Sodium-glucose cotransporter-2
暂未订购 下载PDF
Sodium-glucose co-transporter 2 inhibitors induced euglycemic diabetic ketoacidosis within four days of initiation 认领 引用 被引量：1
17
作者 Almurtada Razok Fateen Ata +1 位作者 Sara Mohamed Ibrahim Ahmed Dabia Hamad S H Al Mohanadi 《World Journal of Diabetes》 SCIE 2022年第3期272-274,共3页
Euglycemic diabetic ketoacidosis(EDKA)is a well-known complication of sodium-glucose co-transporter 2 inhibitors,and many cases with variable onset following the initiation of these agents are reported before,with a m... Euglycemic diabetic ketoacidosis(EDKA)is a well-known complication of sodium-glucose co-transporter 2 inhibitors,and many cases with variable onset following the initiation of these agents are reported before,with a median onset of approximately 2 wk.This letter discusses a 45-year-old lady who initially presented with ischemic stroke but developed EDKA 4 d after starting empagliflozin,a rare occurrence.The patient had severe metabolic acidosis that necessitated admission into the intensive care unit.Prompt discontinuation of empagliflozin and DKA management resulted in clinical recovery. 展开更多
关键词 Euglycemic diabetic ketoacidosis Sodium-glucose co-transporter 2 inhibitors Type 2 diabetes mellitus Empagliflozin
暂未订购 下载PDF
Update on evidence-based clinical application of sodium-glucose cotransporter inhibitors:Insight to uncommon cardiovascular disease scenarios in diabetes 认领 引用
18
作者 Shi-Bing Tao Xi Lu +1 位作者 Zi-Wei Ye Nan-Wei Tong 《World Journal of Diabetes》 SCIE 2024年第7期1461-1476,共16页
In this paper,we concentrate on updating the clinical research on sodium-glucose cotransporter inhibitors(SGLTis)for patients with type 2 diabetes who have heart failure with a preserved injection fraction,acute heart... In this paper,we concentrate on updating the clinical research on sodium-glucose cotransporter inhibitors(SGLTis)for patients with type 2 diabetes who have heart failure with a preserved injection fraction,acute heart failure,atrial fibrillation,primary prevention of atherosclerotic cardiovascular disease/cardiovascular disease,and acute myocardial infarction.We searched the data of randomized controlled trials and meta-analyses of SGLTis in patients with diabetes from PubMed between January 1,2020 and April 6,2024 for our review.According to our review,certain SGLTis(empagliflozin,dapagliflozin,canagliflozin,and tofogliflozin),but not sodium-glucose cotransporter 1 inhibitor(SGLT1i),exhibit relatively superior clinical safety and effectiveness for treating the abovementioned diseases.Proper utilization of SGLTis in these patients can foster clinical improvement and offer an alternative medication option.However,clinical trials involving SGLTis for certain diseases have relatively small sample sizes,brief intervention durations,and conclusions based on weak evidence,necessitating additional data.These findings are significant and valuable for providing a more comprehensive reference and new possibilities for the clinical utilization and scientific exploration of SGLTis. 展开更多
关键词 Sodium-glucose cotransporter inhibitors Diabetes Heart failure Atrial fibrillation Atherosclerosis Cardiovascular disease Acute myocardial infarction
暂未订购 下载PDF
Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure 认领 引用 被引量：8
19
作者 Petra Grubić Rotkvić Maja Cigrovski Berković +2 位作者 Nikola Bulj Luka Rotkvić Ivana Ćelap 《World Journal of Diabetes》 SCIE 2020年第7期269-279,共11页
Three major cardiovascular outcome trials(CVOTs)with a new class of antidiabetic drugs-sodium-glucose cotransporter 2(SGLT2)inhibitors(EMPAREG OUTCOME trial with empagliflozin,CANVAS Program with canagliflozin,DECLARE... Three major cardiovascular outcome trials(CVOTs)with a new class of antidiabetic drugs-sodium-glucose cotransporter 2(SGLT2)inhibitors(EMPAREG OUTCOME trial with empagliflozin,CANVAS Program with canagliflozin,DECLARE-TIMI 58 with dapagliflozin)unexpectedly showed that cardiovascular outcomes could be improved possibly due to a reduction in heart failure risk,which seems to be the most sensitive outcome of SGLT2 inhibition.No other CVOT to date has shown any significant benefit on heart failure events.Even more impressive findings came recently from the DAPA-HF trial in patients with confirmed and well-treated heart failure:Dapagliflozin was shown to reduce heart failure risk for patients with heart failure with reduced ejection fraction regardless of diabetes status.Nevertheless,despite their possible wide clinical implications,there is much doubt about the mechanisms of action and a lot of questions to unravel,especially now when their benefits translated to nondiabetic patients,rising doubts about the validity of some current mechanistic assumptions.The time frame of their cardiovascular benefits excludes glucoselowering and antiatherosclerotic-mediated effects and multiple other mechanisms,direct cardiac as well as systemic,are suggested to explain their early cardiorenal benefits.These are:Anti-inflammatory,antifibrotic,antioxidative,antiapoptotic properties,then renoprotective and hemodynamic effects,attenuation of glucotoxicity,reduction of uric acid levels and epicardial adipose tissue,modification of neurohumoral system and cardiac fuel energetics,sodiumhydrogen exchange inhibition.The most logic explanation seems that SGLT2 inhibitors timely target various mechanisms underpinning heart failure pathogenesis.All the proposed mechanisms of their action could interfere with evolution of heart failure and are discussed separately within the main text. 展开更多
关键词 Sodium-glucose cotransporter 2 inhibitors Heart failure Cardiovascular outcomes Diabetes mellitus Physiological mechanisms Pleiotropic effects
暂未订购 下载PDF
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and metaanalysis 认领 引用 被引量：3
20
作者 Abdulbaril Olagunju Naser Yamani +3 位作者 Dorothy Kenny Martina Mookadam Farouk Mookadam Samuel Unzek 《World Journal of Cardiology》 2022年第11期599-616,共18页
BACKGROUND Landmark trials have established the benefits of sodium-glucose cotransporter-2 inhibitors(SGLT2-Is)in cardiovascular disease including heart failure with reduced and preserved ejection fraction and renal d... BACKGROUND Landmark trials have established the benefits of sodium-glucose cotransporter-2 inhibitors(SGLT2-Is)in cardiovascular disease including heart failure with reduced and preserved ejection fraction and renal diseases regardless of the presence of diabetes mellitus.However,studies evaluating the role of SGLT2-Is in metabolic syndrome(MetS)are limited.AIM This study primarily aimed to evaluate the impact of SGLT2-Is on the components of MetS.METHODS Two independent reviewers and an experienced librarian searched Medline,Scopus and the Cochrane central from inception to December 9,2021 to identify placebo controlled randomized controlled trials that evaluated the impact of SGLT2-Is on the components of MetS as an endpoint.Pre-and post-treatment data of each component were obtained.A meta-analysis was performed using the RevMan(version 5.3;Copenhagen:The Nordic Cochrane Center,The Cochrane Collaboration).RESULTS Treatment with SGLT2-Is resulted in a decrease in fasting plasma glucose(–18.07 mg/dL;95%CI:-25.32 to–10.82),systolic blood pressure(–1.37 mmHg;95%CI:-2.08 to–0.65),and waist circumference(–1.28 cm;95%CI:-1.39 to–1.18)compared to placebo.The impact on highdensity lipoprotein cholesterol was similar to placebo(0.01 mg/dL;95%CI:-0.05 to 0.07).CONCLUSION SGLT2-Is have a promising role in the management of MetS. 展开更多
关键词 Metabolic syndrome Sodium-glucose cotransporter 2 inhibitors Dapagliflozin Empagliflozin Cardiovascular disease
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 5 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈